Aquestive Therapeutics vs BGM Group
Aquestive Therapeutics reported revenue of $44 million in fiscal 2025, 1.2 times BGM Group's $38 million in fiscal 2025. Aquestive Therapeutics' revenue fell 22.6% in its latest year, and BGM Group's grew 51.1%. Aquestive Therapeutics had an operating margin of -159.5%, against -33.2% at BGM Group. Free cash flow was −$53 million at Aquestive Therapeutics and −$4 million at BGM Group. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.
Side by side
| Aquestive Therapeutics | BGM Group | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Sep 30, 2025 |
| Revenue | $44M | $38M |
| Revenue growth | −22.6% | 51.1% |
| Revenue growth a year, last 5 years | −0.6% | −5.4% |
| Gross margin | 58.4% | 16.6% |
| Operating margin | −159.5% | −33.2% |
| Net margin | −188.1% | −52.6% |
| Free cash flow | −$53M | −$4M |
| Free cash flow margin | −119.0% | −10.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 23.3% | 1,467.3% |
| Last close | $3.71 | $8.00 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $2.3 million | — |
| Piotroski F-score | 2 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Aquestive TherapeuticsBGM Group
Operating margin
Percent of revenue
Aquestive TherapeuticsBGM Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aquestive TherapeuticsBGM Group
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aquestive Therapeutics and BGM Group pages.